Improved efficiency and safety Drugs Trolley Ward 11 (2022)

Type of publication:
Service improvement case study

Author(s):
*Parvathy Mohan (Staff Nurse), *Danni Hughes (Sister) and *Angie Boulds (Ward Manager)

Citation:
SaTH Improvement Hub, June 2022

Abstract:
Colleagues are currently covering multiple staffing gaps and each drugs trolley has a variety of drugs and a different layout which could result in delays to patients receiving their medication or receiving the wrong medication in error along with poor staff satisfaction. Following a meeting with the Deputy Director of Nursing- Medicine, it was requested that all wards within the division are planned in to have a review of the drugs trolleys on the ward area and encouraged to utilise 5S principles.

Link to PDF poster [no password required]

Improved efficiency and safety Drugs Trolley (2022)

Type of publication:
Service improvement case study

Author(s):
*Mary Tanes (Ward Manager) and *David Strachan

Citation:
SaTH Improvement Hub, November 2022

Abstract:
Colleagues are currently covering multiple staffing gaps and each drugs trolley has a variety of drugs and a different layout. Variation can result in delays to patients receiving their medication or receiving the wrong medication in error along with poor staff satisfaction. Following a meeting with the Deputy Director of Nursing- Medicine, it was requested that all wards within the division reviewed the drugs trolleys on the ward area and were encouraged to utilise 5S principles.

Link to PDF poster [no password required]

Improved efficiency and safety Drugs Trolley Ward 4 (2022)

Type of publication:
Service improvement case study

Author(s):
*Naomi Roberts and *Leanne Mason (Sisters) and *Sian Silgram (Ward Manager)

Citation:
SaTH Improvement Hub, September 2022

Abstract:
To improve the drugs round process to facilitate improved patient care. Standardisation of ward drugs trolleys to focus on improving patient and staff experience by the end of November 2022.

Link to PDF poster [no password required]

Frontal fibrosing alopecia in men: is it any different? (2022)

Type of publication:
Conference abstract

Author(s):
*Jacob M.A.; *Jain D.; *Shaw R.;

Citation:
British Journal of Dermatology. Conference: 102nd Annual Meeting of the British Association of Dermatologists. Glasgow United Kingdom. 187(Supplement 1) (pp 100), 2022. Date of Publication: July 2022.

Abstract:
Frontal fibrosing alopecia (FFA) is a scarring disease characterized by a receding frontotemporal hairline associated with varying degrees of eyebrow alopecia. It is usually seen in postmenopausal women. FFA has occasionally been reported in men, and can be confused with androgenetic alopecia, and therefore present quite late to the clinician. Although, histopathologically, FFA is similar in both sexes, there are a few differences clinically and with regard to treatment. We aimed to highlight these characteristics. A 51-year-old male presented with hair loss of 3 years' duration involving the eyebrows, sideburns and beard, followed by frontotemporal recession of the hairline. He reported a similar history in his mother and maternal aunt. In addition, he was known to have testosterone deficiency with low levels of total and free testosterone and sex hormone binding globulin, and was on replacement therapy. His remaining serology, including thyroid profile, was within normal limits. Clinical examination showed patchy alopecia of the eyebrows, eyelashes, sideburns and beard. There was frontotemporal recession of hairline along with loss of follicular orifices and perifollicular erythema. Additionally, he had diffuse thinning of the hair over the vertex and nonscarring alopecia over his extremities. A punch biopsy showed end-stage scarring alopecia with perifollicular fibrosis and 'backing off' of the surrounding lichenoid inflammatory infiltrate consistent with lichen planopilaris. A clinical diagnosis of FFA was made and the patient was started on hydroxychloroquine tablets along with 1% topical pimecrolimus twice daily over the patches of alopecia on the face. Common sites of hair loss in men include the sideburns, beard, eyebrows, eyelashes and occipital hair, and facial hair loss may precede eyebrow loss, as was the case in our patient. Facial papules, androgenetic alopecia and loss of body hair are more often observed in men with FFA than in women. In addition, the loss of body hair and eyelashes and the presence of facial papules have been associated with more severe forms of FFA and can be used as a prognostic indicator. Autoimmune conditions like thyroid disease and lichen planus are uncommon in males, although androgen deficiency has been linked to FFA in males in various studies. In addition, hormone-blocking drugs can contribute to FFA. Therefore, it is very important to keep this in mind during history and examination and perform relevant blood tests. In addition, treatment with minoxidil may provide better results in males.

A case of BASCULE (Bier anaemic spots associated with cyanosis and urticaria-like eruption) syndrome associated with postural hypotension. (2022)

Type of publication:
Conference abstract

Author(s):
*Shaw, Roberta; *Oliwieckim Simone

Citation:
British Journal of Dermatology. Conference: 102nd Annual Meeting of the British Association of Dermatologists. Glasgow United Kingdom. 187(Supplement 1) (pp 206), 2022. Date of Publication: July 2022.

Abstract:
A 15-year-old boy presented to the paediatric dermatology clinic with an unusual bilateral intermittent rash to his lower legs, which he had noticed for many years. The patient demonstrated multiple irregular white macules and urticated papules on a background of cyanosis of the legs when standing for prolonged periods, such as in the shower, and which was relieved by sitting. The mother believed that the rash began after a flu-like illness, and aside from this he was usually fit and well, with no significant past medical history, family history or regular medications. The patient had a full blood screen, including coagulation screen, which were normal. The patient described an intermittent lightheaded sensation on standing. Therefore, while in clinic the patient had a lying and standing blood pressure, which demonstrated a significant systolic drop from 137 mmHg lying to 109 mmHg standing, while his heart rate remained stable. The clinical findings suggested a diagnosis of BASCULE syndrome. BASCULE syndrome is a benign vasomotor dermatosis first described in 2016. The clinical findings described include Bier anaemic spots, cyanosis and urticaria-like eruption. The pathogenic mechanism remains unknown but is thought to be associated with transient tissue hypoxia through arteriolar vasoconstriction causing a paradoxical urticated rash that is worse on standing. Although BASCULE syndrome has been described as a separate entity, there have been links to POTS (postural orthostatic tachycardia syndrome) and orthostatic acrocyanosis, and so these diagnoses should be considered when investigating a patient with similar features.

An Assessment of Factors That Influence Outcome Following Fixation of Periprosthetic Distal Femur Fractures Associated with Total Knee Arthroplasty (2022)

Type of publication:
Journal article

Author(s):
*Fakoya, Keji; *Sedarous, Ramy; *Seifo, Mina; *Okoro, Tosan

Citation:
Ortopedia Traumatologia Rehabilitacja. 24(3):193-199, 2022 Jun 30.

Abstract:
BACKGROUND: Periprosthetic distal femur fractures following total knee arthroplasty (PDFFTKA) are increasingly common [1], mainly in elderly patients with significant co-morbidities [2]. Surgical management usually requires balancing prompt fixation for early mobilization with the need to consider the least physiologically demanding option [3]. The aim of this study was to assess predictors of clinical and radiological outcome in patients with PDFFTKA treated with open reduction and internal fixation (ORIF). MATERIALS AND METHODS: A retrospective cohort study of patients managed for PDFFTKA over the last 21 years in the Trauma & Orthopaedics Department of the Royal Shrewsbury Hospital (RSH) was carried out. Radiological images, pre- and post-operatively, were assessed for fracture related parameters. Last known functional status was evaluated using the most recent outpatient review letters. After assessment of normality of data, evaluation of predictors of clinical and radiological outcome was made using correlation analyses. RESULTS: There was no statistically significant correlation between age, primary TKA to fracture interval, and length of intact medial cortex vs clinical outcome for the parametric variables evaluated. For non-parametric variables assessed, there was a statistically significant correlation between clinical outcome and evidence of callus formation (Spearman rho value -0.476; p=0.022). In stratifying the patients with poor and good outcome, there was no difference noted in primary TKA to fracture interval, or length of intact medial cortex (mm) between both groups. In terms of the number of comminuted fragments and anterior flange to fracture distance (mm), there was also no difference noted between the poor and good functional groups. CONCLUSIONS: 1. There was no observed correlation in pre-operative patient and fracture related variables with outcome in this population of patients with PDFFTKA. 2. Post-operative evidence of callus formation appears to be directly related to better clinical outcomes.

Link to full-text [NHS OpenAthens account required]

Treatment and outcomes of patients with gastrointestinal toxicity following immunotherapy: A large multi-center retrospective study in the United Kingdom by the National Oncology Trainees Collaborative for Healthcare Research (NOTCH) (2022)

Type of publication:
Conference abstract

Author(s):
Swaminathan M.; Angelakas A.; Baxter M.; Cotton J.; Dobeson C.B.; Feeney L.; Gault A.C.; Hughes D.J.; Jones C.; Lee R.; Mughal S.A.; *Parikh S.P.; Pritchard M.; Rodgers L.J.; Rowe M.P.; Salawu A.T.; Shotton R.; Tinsley N.; Tivey A.; Olsson-Brown A.C.;

Citation:
Immuno-Oncology and Technology. Conference: ESMO Immuno-Oncology Congress 2022. Geneva Switzerland. 16(Supplement 1) (no pagination), 2022. Article Number: 100230. Date of Publication: December 2022.

Abstract:
Background: Immune checkpoint inhibitors (ICIs) have revolutionised the treatment of many cancers, but their use has been associated with the development of gastrointestinal (GI) toxicities such as colitis and hepatitis. Method(s): A multi-center retrospective study across 12 National Health Service centers across the United Kingdom (UK) was conducted by the UK National Oncology Trainees Collaborative for Healthcare Research (NOTCH) over a 2-year period. The study included patients receiving ICIs for malignant melanoma, non-small lung cancer and renal cell cancer as standard of care. Occurrence of clinically significant (>=grade 2) GI toxicity was assessed and correlated with subsequent treatment and outcomes. Multiple logistic regression was used to assess correlation. For overall survival (OS), Kaplan-Meier and log-rank tests were utilised. Result(s): The cohort included 2049 patients. 1230 (60%) were male with a median age of 66. Colitis occurred in 182 (8.9%) patients and hepatitis in 129 (6.3%). Of the patients where treatment was recorded, 129 (70.9%) received treatment with systemic steroids alone and 37 (20.3%) required second-line immunosuppressants (IS) in the colitis group. In the hepatitis group, 101 (78.3%) had steroids alone with 19 (14.7%) having IS. Improved OS was found in patients who experienced colitis (HR 2.59 95%CI: 2.15 to 3.11, p<0.0001) and hepatitis (HR 2.26, 95%CI: 1.84 to 2.79, p=<0.0001) compared to those with no adverse events. Pre-existing autoimmune disease (p=0.02) and combination ICIs (p=0.006) were predictors of colitis that required IS whilst grade 2 and 3 hepatitis (p<0.001) were predictors of hepatitis needing IS. The use of IS did not affect OS significantly in the colitis group (p=0.372) but did correlate with survival in the hepatitis group (p=0.037). Patients that were able to continue treatment with ICIs after toxicity had an increased OS in both groups (p<0.001). Conclusion(s): Patients with GI toxicity following treatment with ICIs have improved OS. The use of IS did not significantly affect OS which suggests they should continue to be utilised in the treatment of GI toxicity. Legal entity responsible for the study: United Kingdom National Oncology Trainees Collaborative for Healthcare Research (NOTCH).

Link to full-text [no password required]